Minerva Neurosciences Inc
Company Profile
Business description
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Contact
1500 District Avenue
BurlingtonMA01803
USAT: +1 617 600-7373
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
stocks
Our top ASX picks in every sector
stocks
Potentially catastrophic ruling for ASX company
stocks
4 charts on Nvidia’s record $4 trillion market cap
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,854.50 | 39.20 | 0.44% |
CAC 40 | 7,808.17 | 21.12 | -0.27% |
DAX 40 | 24,160.64 | 94.67 | -0.39% |
Dow JONES (US) | 44,459.65 | 88.14 | 0.20% |
FTSE 100 | 8,998.06 | 56.94 | 0.64% |
HKSE | 24,479.98 | 276.66 | 1.14% |
NASDAQ | 20,640.33 | 54.80 | 0.27% |
Nikkei 225 | 39,570.24 | 110.62 | 0.28% |
NZX 50 Index | 12,679.36 | 0.67 | 0.01% |
S&P 500 | 6,268.56 | 8.81 | 0.14% |
S&P/ASX 200 | 8,610.70 | 40.30 | 0.47% |
SSE Composite Index | 3,523.27 | 3.62 | 0.10% |